AbbVie is a pharmaceutical company that manufactures adalimumab (Humira®), a tumor necrosis factor (TNF) blocker indicated for treatment of moderately to severely active rheumatoid arthritis and moderately to severely active Crohn’s disease (among other conditions). MotherToBaby Pregnancy Studies completed the Humira® & Pregnancy Study as an independent research entity to monitor the outcomes of females who take this medication during pregnancy. Read our findings.

Amgen is the biotechnology company that produces evolocumab (Repatha®), a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody indicated for the treatment of atherosclerotic cardiovascular disease (ASVCD) and familial hypercholesterolemia (FH). Amgen also manufactures etanercept (Enbrel®), a tumor necrosis factor (TNF) blocker indicated for the treatment of: rheumatoid arthritis polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Amgen also acquired from Celgene apremilast (Otezla®), an inhibitor of phosphodiesterase 4 (PDE4) that is indicated for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. MotherToBaby Pregnancy Studies coordinates the Repatha® & Pregnancy Study, the Enbrel® & Pregnancy Study, and the Otezla® & Pregnancy Study as an independent research entity to monitor the outcomes of females who take these medications during pregnancy.

AstraZeneca is a biopharmaceutical business that produces benralizumab (Fasenra™), an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. MotherToBaby Pregnancy Studies conducts the Fasenra™ & Pregnancy Study as an independent research entity to monitor the outcomes of females who take this medication during pregnancy.

GSK is the pharmaceutical manufacturer of mepolizumab (Nucala®), an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated as an add-on maintenance treatment for patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype. MotherToBaby Pregnancy Studies leads the Nucala® & Pregnancy Study as an independent research entity to monitor the outcomes of females who take this medication during pregnancy.

Leflunomide is a pyrimidine synthesis inhibitor belonging to the disease-modifying antirheumatic drug (DMARD) class. It is indicated for the treatment of adult moderate-to-severe rheumatoid arthritis, and was originally marketed under the brand name Arava®. Pharmaceutical companies manufacturing generics of leflunomide participate in a consortium to monitor the effects of this these products when used in pregnancy. MotherToBaby Pregnancy Studies runs the Leflunomide & Pregnancy Study as an independent research entity to monitor the outcomes of females who take this medication during pregnancy.

Janssen is a Johnson & Johnson pharmaceutical company that produces guselkumab (Tremfya®), an interleukin-23 blocker indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis. Janssen also manufactures ustekinumab (Stelara®), a human interleukin-12 and -23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderate-to-severely active Crohn’s Disease, and moderate-to-severely active ulcerative colitis. MotherToBaby Pregnancy Studies is carrying out the Tremfya® & Pregnancy Study as well as the Stelara® & Pregnancy Study as an independent research entity to monitor the outcomes of females who take these medications during pregnancy.

Pfizer is a biopharmaceutical company that produces the prescription medication tofacitinib (Xeljanz®), a Janus kinase (JAK) inhibitor indicated for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis, or moderately to severely active ulcerative colitis. With BioNTech, Pfizer also developed and produces an mRNA vaccine to prevent COVID-19 infection. MotherToBaby Pregnancy Studies coordinates both the Xeljanz® & Pregnancy Study and the Pfizer-BioNTech COVID-19 Vaccine & Pregnancy Study as an independent research entity to monitor the outcomes of individuals who take Xeljanz® or receive the Pfizer-BioNTech vaccine during pregnancy.

Regeneron is the biotechnology company that makes the prescription medicine dupilumab (Dupixent®), an interleukin-4 receptor alpha antagonist indicated for the treatment of moderate-to-severe atopic dermatitis or as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype. MotherToBaby Pregnancy Studies administers the Dupixent® & Pregnancy Study as an independent research entity to monitor the outcomes of females who take this medication during pregnancy.

Roche is the pharmaceutical company that produces the prescription medicine tocilizumab (Actemra®), an interleukin-6 (IL-6) receptor antagonist indicated for treatment of moderately to severely active rheumatoid arthritis, active polyarticular or systemic juvenile idiopathic arthritis, and giant cell arteritis. MotherToBaby Pregnancy Studies directs the Actemra® & Pregnancy Study as an independent research entity to monitor the outcomes of females who take this medication during pregnancy.

Sanofi is a biopharmaceutical company that produces the prescription medication sarilumab (Kevzara®), a interleukin-6 (IL-6) receptor antagonist indicated for treatment of moderately to severely active rheumatoid arthritis. Sanofi also manufactures teriflunomide (Aubagio®), a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis. MotherToBaby Pregnancy Studies conducts the Kevzara® & Pregnancy Study as well as the Aubagio® & Pregnancy Study as an independent research entity to monitor the outcomes of females who take these medications during pregnancy. Sanofi also manufactures leflunomide (Arava®), a pyrimidine synthesis inhibitor indicated for the treatment of adult moderate-to-severe rheumatoid arthritis. MotherToBaby Pregnancy Studies completed the pregnancy registry for this product; read findings from our Arava® & Pregnancy Study.

Sun Pharma is the pharmaceutical company that makes tildrakizumab-asmn (Ilumya™), an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis. MotherToBaby Pregnancy Studies facilitates the Ilumya™ & Pregnancy Study as an independent research entity to monitor the outcomes of females who take this medication during pregnancy.

Takeda is the pharmaceutical company that has developed the prescription medication vedolizumab (Entyvio®), an integrin receptor antagonist indicated in adults for the treatment of moderate-to-severely active Crohn’s Disease and moderate-to-severely active ulcerative colitis. MotherToBaby Pregnancy Studies coordinates both the Entyvio® & Pregnancy Study and the Motegrity® & Pregnancy Study as an independent research entity to monitor outcomes of individuals who take these medications during pregnancy.

UCB is a biopharmaceutical company that manufactures certolizumab pegol (Cimzia®), a tumor necrosis factor (TNF) blocker indicated to reduce the signs and symptoms of Crohn’s disease as well as for the treatment of moderately-to-severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderate-to-severe plaque psoriasis. MotherToBaby Pregnancy Studies directs the Cimzia® & Pregnancy Study as an independent research entity to monitor the outcomes of females who take this medication during pregnancy.

Dr. Romeo works at the Utah Department of Health with MotherToBaby Utah’s Pregnancy Risk Line as an information specialist. His experiences include working as a nurse in newborn intensive care; teaching college health education classes; training medical homes in improving services for children with special health care needs; training young adults with disabilities in leadership and advocacy; and helping families learn about child development. He has served as OTIS Secretary and as Chair of various OTIS committees.

Angela is an information specialist with MotherToBaby California. She earned her undergraduate degree in psychology from Chapman University and her graduate degree from Kansas State University in academic advising/counseling. Angela has been with MotherToBaby since 2009, with experience in both research and counseling. She appreciates the opportunity to speak with people who are pregnant and/or breastfeeding and healthcare professionals regarding exposures and medications, and holds a special interest in stress and anxiety in pregnancy and breastfeeding.

Beth is a genetic counselor and pediatric nurse practitioner. She established the Nebraska Teratogen Information Service in 1986, also known as MotherToBaby Nebraska. She was also a founding board member of OTIS.

In her clinical practice, Beth sees patients in General Genetics Clinic, Prenatal Clinic, and the Fetal Alcohol Syndrome Clinic at the University of Nebraska Medical Center. Beth has provided consultation to the FDA and CDC. Two of her recent publications are, “The Art and Science of Teratogen Risk Communication” and “Safety Concerns Regarding Binge Drinking in Pregnancy: A Review”.

Bridget is a board-certified genetic counselor and teratology information specialist at MotherToBaby Arizona. In addition to providing exposure counseling by phone, email, and online chat, she is a member of the MotherToBaby Fact Sheet Team, where she creates MotherToBaby exposure fact sheets. She is also a clinical instructor in the College of Pharmacy at the University of Arizona, where she educates health professionals and graduate-level students on clinical genetics and teratology. Bridget received her Master of Science in Genetic Counseling from the University of Arizona in 2024.

Brigitte has worked as a perinatal pharmacist for over 20 years at CHU Sainte-Justine, a tertiary mother-and-child hospital in Montreal, Quebec. She divides her time between NICU and centre IMAGe, where she shares her expertise as a counselor and coordinator since 2003.

Over the years, she published numerous articles in professional journals and presented several conferences on drugs in pregnancy and breastfeeding. She is one of the co-editors of the book Grossesse et Allaitement: Guide thérapeutique (Pregnancy and Breastfeeding: Therapeutic Guide); the 3^rd edition is will be published in 2021-2022.

Caroline has worked as aninformation specialist with Centre IMAGe (Montréal, Québec) since 2002. She also works as a clinical pharmacist in Obstetric and Gynecology at CHU Sainte-Justine, a mother and child university hospital center. She co-edited the 2^nd edition of Grossesse et allaitement – guide thérapeutique (Pregnancy and Breastfeeding: Therapeutic Guide), a book on pharmacotherapy published to support health care providers working with people who are pregnant and/or breastfeeding.

Chris is a board-certified genetic counselor based in Tucson, Arizona. Her counseling experience includes pharmacogenetics as well as reproductive and cardiac genetics. She is the Program Coordinator and an information specialist at MotherToBaby Arizona, located at the University of Arizona. Chris is also Clinical Coordinator and Clinical Instructor for the University of Arizona Genetic Counseling Graduate Program, Clinical Instructor in Pharmacy Practice-Science, and the host of the MotherToBaby Podcast.

Christianne Senechal is an information specialist with MotherToBaby Connecticut, where she has worked since 2022. She holds a Master of Science in Health Care Genetics and will graduate with a Master of Science in Genetics Counseling from the University of Connecticut in 2026. Christianne is passionate about providing accessible, evidence-based counseling on exposures during pregnancy and breastfeeding to both the public and healthcare professionals, supporting patients in making informed decisions that are best for their health and their baby.

Dr. Coles is Director of MotherToBaby Georgia and Professor of Psychiatry and Behavioral Sciences and Pediatrics at Emory University, where she is also Director of the Maternal Substance Abuse and Child Development Laboratory. Her expertise is in the developmental and behavioral effects of prenatal exposure to drugs and alcohol and the interaction of these effects with the postnatal environment. She was among the first to describe the behavioral effects of prenatal alcohol exposure and to investigate the effects of cocaine exposure on child development.

Ema completed a bachelor’s and a master’s degree in pharmacy from Université de Montréal, a doctorate of pharmacy at the University of British Columbia, and a residency in perinatology at BC Women and Children’s Hospital and Long Beach Memorial Hospital. She has a joint position between CHU Ste-Justine and Faculty of Pharmacy where she is a full clinical professor teaching OB/GYN therapeutics. She is actively involved in patient care and research projects, andco-directed the publication of two editions of “Grossesse et allaitement: Guide thérapeutique” (Pregnancy and Breastfeeding: Therapeutic Guide). A third edition will be published in 2021-2022.

Jessie Poskochil is a board certified genetic counselor and assistant professor at the University of Nebraska Medical Center (UNMC) in Omaha, NE. Jessie earned her Master of Genetic Counseling (MGC) degree from UNMC in 2021. In her clinical practice, Jessie sees patients for a variety of hereditary cancer indications. She is a course instructor, clinical supervisor, and capstone committee member for students in the UNMC Genetic Counseling Education Program and enjoys co-instructing the Embryology and Teratology classes. As a teratogen information specialist for MotherToBaby Nebraska, Jessie provides counseling to clients and providers via chat, text, and phone. 

Josianne is a pharmacist who graduated from the University of Montreal with a master’s degree in advanced pharmacotherapy for hospital practice. She works at Centre IMAGe, a MotherToBaby information service located at CHU Sainte-Justine, a tertiary mother-child university hospital in Montreal. She practices pharmaceutical care in the neonatal intensive care unit. As an associate clinician, she supervises pharmacy students and residents during their hospital training. She is the author of several articles and book chapters on pharmacotherapy during pregnancy and lactation and contributes to the activities of the Centre IMAGe. She has been a member of OTIS since 2008.

Kate Mowrey is a genetic counselor and clinical instructor in the Department of Pediatrics, Division of Medical Genetics at McGovern Medical School at The University of Texas Health Science Center at Houston.  In addition to being an information specialist for MotherToBaby TexasTIPS, Kate assists in the LoneStar Leadership Education in Autism and Neurodevelopmental Disabilities (LEND) Program as well as the UT Tuberous Sclerosis Center of Excellence. Furthermore, her responsibilities include clinical coordination and providing genetic counseling to pediatric patient families in general genetics as well as neurology clinics. She is involved in teaching and supervising students for the University of Texas Genetic Counseling Training Program. Kate graduated from The University of Texas at Austin in 2014 with a BS in Human Biology, concentration in Genetics and Biotechnology and received her MS in Genetic Counseling from Genetic Counseling from the University of Texas Health Science Center at Houston in May 2018.

Kirstie Perrotta is an information specialist at MotherToBaby California, where she provides counseling by phone and chat. She received her Masters in Public Health (MPH) from the University of San Francisco, and has worked in the field of reproductive health for over 9 years. Kirstie currently serves as a member of the MotherToBaby Emerging Issues Task Force (EITF), which provides leadership around our COVID-19 response. Her interests include vaccines, infectious disease, and mental health during pregnancy.

Leah is the Program Coordinator for MotherToBaby Georgia. She received her Bachelor of Science in Nursing from Illinois Wesleyan University and is a registered nurse. Her nursing experience includes fertility medicine and primary care. She recently completed her Master of Public Health at Emory University with a specialization in behavioral, social, and health education sciences. Leah is a Certified Health Education Specialist. She has experience in providing sex and reproductive health education to children and adults. When she isn’t the Program Coordinator for MotherToBaby Georgia, Leah still volunteers as a public health nurse. Leah is passionate about having hard conversations about health, as well as health literacy, health integrity, and health empowerment.

Lori is a board certified genetic counselor and the Director of MotherToBaby North Texas, which is part of the Texas Teratogen Information Service (TIS). Lori began the Texas TIS in July of 1991. In addition to running the Texas TIS, Lori provides community workshops and education to both the public and to health care providers, and teaches at the University of North Texas. Lori is happily married to Doug, and is the mother of three wonderful children, two of whom are adopted.

Lorrie Harris-Sagaribay is the Program Coordinator and Lead Information Specialist at MotherToBaby North Carolina. She provides exposure counseling in English and Spanish by phone, email, and online chat, as well as conducting outreach and providing professional education and guest lectures on teratology. She currently serves on the OTIS Board of Directors and co-chairs the MotherToBaby Emerging Issues Task Force. After serving with the Peace Corps in Honduras, Lorrie earned her Masters of Public Health from the University of North Carolina at Chapel Hill with a concentration in maternal and child health. She enjoys helping people make informed decisions about medications and other exposures during pregnancy and breastfeeding.

Mara is a certified genetic counselor who for the past 16 years has been providing pregnancy and breastfeeding exposure information by phone and email. As an information specialist for MotherToBaby California, she now also provides information through the MotherToBaby online chat. Her prior professional experience includes working at a neuromuscular genetics lab, at a muscular dystrophy and ALS clinic, and at two prenatal genetic practices. Academically, she earned her undergraduate degree from Cornell University and her master’s degree from Northwestern University.

Myla is a certified genetic counselor and clinical instructor in the Department of Pediatrics, Division of Genetics at the University of Texas Medical School. In addition to being an information specialist for MotherToBaby TexasTIPS, she provides genetic counseling to families of pediatric patients at the Shriners Hospitals for Children in Houston. She is involved in facilitating courses and supervising students from the University of Texas Genetic Counseling Training Program. Myla graduated from Ohio Wesleyan University with a BA in Genetics and received her MS in Human Genetics and Genetic Counseling from Stanford University.

Nevena is a board certified genetic counselor and an assistant professor at the University of South Florida (USF), division of Maternal Fetal Medicine and serves as the Program and Research Coordinator at MotherToBaby Florida. In addition to providing counseling as an information specialist at MTB Florida and USF Exposures Clinic, she provides prenatal and preconception genetic counseling in various clinics across the Tampa Bay area. She provides both clinical supervision and coursework instruction for students form the USF Genetic Counseling Program. Nevena earned her MS in Genetic Counseling from the University of Texas Health Science Center in Houston in 2012.

Réka is a board certified genetic counselor and clinical instructor at the University of South Florida (USF), division of Maternal Fetal Medicine. In addition to providing counseling as an information specialist at MotherToBaby Florida and USF Exposures Clinic, she provides prenatal and preconception genetic counseling in various clinics in the Tampa Bay area. She also provides clinical supervision and coursework instruction for students form the USF Genetic Counseling Program. Réka, originally from Budapest, Hungary, earned her MSPH in Genetic Counseling from the University of South Florida in 2019.

Dr. Običan is the Medical Director of MotherToBaby Florida. She is a board-certified obstetrician/gynecologist specializing in maternal-fetal medicine, with particular research and clinical interest in teratology, fetal echocardiography and fetal therapy. She completed her Doctor of Medicine at the University of Miami School of Medicine, a residency in Obstetrics and Gynecology at George Washington University, and maternal-fetal medicine fellowship training at the Columbia University Medical Center. She is also fellowship trained in reproductive teratology and toxicology. Dr. Običan is an Assistant Professor at the University of South Florida in the Department of Obstetrics and Gynecology, division of Maternal Fetal Medicine. 

Sharon has worked for MotherToBaby Connecticut for more than 28 years, the last eighteen of which she has served as the Coordinator. She is also currently the Research Coordinator representing her service. Sharon is a clinical Instructor in the Division of Human Genetics, Department of Genetics and Genome Sciences at UConn Health in Farmington, CT. She graduated from Northeastern University and went on to receive a Master’s of Science in Human Genetics/Genetic Counseling from Sarah Lawrence College. Sharon’s research interest lies in psychiatric diseases in pregnancy and their treatment, and prevention of prenatal isotretinoin exposures.

Sonia is a bilingual (Spanish/English) information specialist with MotherToBaby California. Along with answering people’s and health professionals’ questions regarding exposures during pregnancy and breastfeeding via phone, email, and live chat, she provides educational talks in the community regarding pregnancy health and supports the activities to promote MotherToBaby’s services. In addition, Sonia has authored several MotherToBaby Blogs and has translated content into Spanish. She has also served in leadership and member roles for several OTIS Committees, including the Education Committee, Abstract Committee and Marketing and Website Committees.

Dr. Chambers is Professor of Pediatrics and Family Medicine and Public Health at the University of California San Diego (UC San Diego), Clinical Professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego, and the Director of Clinical Research at Rady Children’s Hospital San Diego. She is a perinatal epidemiologist who leads a number of national and international complex longitudinal cohort studies and clinical trials of prenatal exposures and child health and development. Her research has been instrumental in identifying previously unrecognized human teratogens, as well as ruling out substantial risk for other medications and vaccines. In addition to being the lead investigator of MotherToBaby Pregnancy Studies, Dr. Chambers is the Program Director of the MotherToBaby California affiliate. She is also a founding principal investigator for the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS), which is the first national system to evaluate medication and vaccine safety in human pregnancy.

Dr. Jones is Distinguished Professor and Chief of the Division of Dysmorphology and Teratology in the Department of Pediatrics at the University of California San Diego. He is also Medical Director of the MotherToBaby California affiliate, which he founded in 1979. Dr. Jones received his M.D. from Hahnemann Medical School, and completed a pediatric internship at Philadelphia General Hospital and a pediatric residency at the University of Washington in Seattle. His research has focused on the clinical detection of birth defects and the mechanisms of normal and abnormal growth of tissues and organs during development. He is board certified in Pediatrics, and performs infant physical examinations for MotherToBaby Pregnancy Studies.

Dr. Haldeman-Englert is a clinical geneticist, and serves as the medical director for the Cone Health Precision Health program. His clinical responsibilities include pediatric and adult care at Cone Health, and is the principal investigator of the Cone Health population genomic screening program. He received his M.D. from Penn State University College of Medicine, completed an internship and residency in pediatrics and internal medicine at Valleywise Health and Phoenix Children’s Hospital, and a fellowship in clinical genetics at Children’s Hospital of Philadelphia and University of Pennsylvania. He is board certified in clinical genetics, and performs infant physical examinations for MotherToBaby Pregnancy Studies.

Dr. Adam is Professor in the Division of Genetic Medicine, Department of Pediatrics at the University of Washington. Her clinical responsibilities include pediatric care at Seattle Children’s Hospital, as well as counseling people who are pregnant through the Prenatal Diagnosis Center at the University of Washington. She received her M.D. from Stanford University School of Medicine, and completed an internship and residency in Pediatrics at the Lucile Salter Packard Children’s Hospital at Stanford and a fellowship in Medical Genetics at Stanford University Hospital. She is board certified in Medical Genetics and Pediatrics, and performs infant physical examinations for MotherToBaby Pregnancy Studies.

Dr. del Campo Casanelles is a medical geneticist and Clinical Professor in the Department of Pediatrics at the University of California San Diego. He cares for patients with dysmorphologic, genetic, and teratologic conditions at Rady Children’s Hospital-San Diego and conducts clinical research projects in the Division of Dysmorphology and Teratology at UCSD. He is board certified in both Clinical Genetics and performs infant physical examinations for MotherToBaby Pregnancy Studies.

Dr. Braddock is Professor of Pediatrics and Director of Medical Genetics at Saint Louis University in St. Louis, Missouri. He received his M.D. from the University of Missouri-Columbia School of Medicine in 1988, completed an internship and residency in Pediatrics at the University of Utah and fellowships in Medical Genetics at Cedars-Sinai Medical Center/UCLA in Los Angeles and in Dysmorphology and Teratology at the University of California San Diego. He is board-certified in both Pediatrics and Medical Genetics, and performs infant physical examinations for MotherToBaby Pregnancy Studies.

Dr. Adams is the Director of Neurodevelopmental Follow-up for MotherToBaby Pregnancy Studies at UC San Diego Department of Pediatrics and Professor of Psychology at the University of Massachusetts Boston (1988 – 2020). Throughout her career, Dr. Adams has conducted research of regulatory and clinical relevance within the field of neurobehavioral teratology with a primary focus on the effects of prenatal exposure to certain prescription medications upon the neurobehavioral development of the child. She has held several elected positions and been an active member in both the Society for Birth Defects Research and Prevention and the Developmental Neurotoxicology Society.

Dr. Janulewicz Lloyd is an Assistant Professor in the Environmental Health Department at Boston University, School of Public Health. She received her Bachelor of Science degree from the University of Massachusetts, under the tutelage of Dr. Jane Adams. She continued her education at Boston University, receiving a Masters in Public Health and Doctor of Science degree in Environmental Health.  Dr. Janulewicz Lloyd has worked with MotherToBaby California for the past 11 years and recently became the Associate Director of the Neurodevelopmental Follow-Up Program, under the direction of Dr. Adams.  In her free time, Dr. Janulewicz Lloyd likes to spend her time with her husband, Nathanael, their three children (Eric, Eleanor and Caroline), and their dog Marley.

Kelly Kao is the Program Manager of the Neurodevelopmental Follow-Up Program at the UC San Diego Center for Better Beginnings, where she oversees the team of psychometrists that conducts developmental assessments for the Center’s research programs, including MotherToBaby Pregnancy Studies. She has been with Division of Environmental Science & Health since 1993. Kelly obtained her Bachelor’s degree in Sociology at the UC San Diego with minors in Biology and Spanish Literature. She became interested in prenatal environmental exposures that cause birth defects and long-term developmental effects when she took a Sociology of Law course that examined the death penalty case of a man who was diagnosed with Fetal Alcohol Syndrome (FAS). She actively demonstrates her dedication to educating the community about prenatal environmental exposures through her outreach activities, lectures, and research projects.

Robert is a senior information specialist based at MotherToBaby California. He also serves as Stakeholder Liaison for the OTIS National Office, where he cultivates new partnerships with healthcare providers/administrators and a number of national programs for under-served populations. He attends and participates at national conferences such as the Association of Maternal & Child Health Programs (AMCHP), National Healthy Start, National WIC, Postpartum Support International, Primary Care Association and March of Dimes to strengthen OTIS’ community engagement. Robert has also served as President, Secretary, and Member-At-Large of OTIS’s Board of Directors.

Violet Webb is a Psychometrist and Research Associate in the Developmental Follow-Up Program at MotherToBaby. She attended San Francisco State University where she received her Bachelor’s Degree in Psychology. In 2017, she went on to receive her Masters of Science and Advanced Certificate in Educational Psychology from CUNY Brooklyn. Violet is passionate about working with children and contributing to the research that will provide insight about child development. Her goal is to provide assessments that are both fun and comfortable for parent and child.